Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (NASDAQ: EOLS) will announce its first quarter 2022 financial results on May 10, 2022, after U.S. market close. Following the release, management will host a conference call at 4:30 p.m. ET for discussion, followed by a Q&A session. Investors can join via phone at (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through a live webcast on the Evolus website. A replay of the call will be available afterward. Evolus focuses on customer-centric breakthrough products in the aesthetics market, with Jeuveau® as its flagship neurotoxin.
Evolus, Inc. (NASDAQ: EOLS) has enrolled its first patient in a pivotal clinical study assessing an ‘extra-strength’ dose of Jeuveau® (prabotulinumtoxinA-xvfs), designed for aesthetic use. This multicenter, double-blind trial will involve 150 patients and compare the efficacy of 40 units of Jeuveau® against the standard 20-unit doses of Jeuveau® and BOTOX® Cosmetic. The company anticipates study completion in the first half of 2023, aiming to address a need in the aesthetic market, as clinicians have expressed interest in a stronger dosage option.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 15, 2022, from 1:35-2:00 p.m. ET. The event emphasizes Evolus’ commitment to delivering innovative products, including their FDA-approved neurotoxin, Jeuveau®, which focuses on aesthetic applications. The presentation will be accessible via an audio webcast on Evolus’ investor relations website, with a replay available for 90 days post-event.
Evolus reported Q4 2021 net revenue of $34.7 million, a 68% increase year-over-year. Full-year 2021 revenue reached $99.7 million, up 76% from 2020. The company reaffirmed guidance for 2022 revenues between $143 million and $150 million, projecting growth of 43% to 50%. Evolus added 400 new customer accounts in Q4 and achieved significant marketing successes, including over 1 billion impressions. Despite losses from operations reducing by 83%, the company is on track for growth, aiming for better profit margins post-settlement royalty reductions in September 2022.
Evolus, Inc. (NASDAQ: EOLS) announces the retirement of Chief Financial Officer Lauren Silvernail, effective May 31, 2022, after nearly four years with the company. During her tenure, she significantly contributed to the company's growth, leading efforts in commercial infrastructure and balance sheet restructuring. Silvernail also negotiated a $125 million credit facility to support the company through cash flow breakeven, positioning Evolus for future success. The search for her successor is already underway.
Evolus, Inc. (NASDAQ: EOLS) announced the appointment of Christos Monovoukas as Senior Vice President of Corporate Development, effective February 28, 2022. Monovoukas has over 20 years of experience in business development, previously serving at Olympus Corporation and Smith & Nephew. In connection with his hiring, Evolus granted him inducement awards consisting of options for 171,103 shares and 39,012 RSUs, with an exercise price of $9.15. CEO David Moatazedi expressed confidence in Monovoukas' ability to support the company's growth strategy.
Evolus, Inc. (NASDAQ: EOLS) announced it will report its fourth quarter and year-end 2021 financial results on March 3, 2022, after U.S. market close. A conference call and live webcast will follow at 4:30 p.m. ET, including a Q&A session. Participants can join via phone or through the Evolus website. A replay of the call will be available after completion. Evolus, known for its neurotoxin Jeuveau®, focuses on redefining the aesthetic market with innovative customer-centric products.
Evolus, Inc. (NASDAQ: EOLS) has announced that its submission for regulatory approval of Nuceiva® (prabotulinumtoxinA) has been accepted by the Australian Therapeutics Good Administration (TGA). This is a significant milestone for the company's international growth strategy, as Australia represents one of the largest global markets for aesthetics. Nuceiva® is already approved in the U.S. as Jeuveau®, and in Europe and Canada. Evolus aims to complete the TGA approval process in 2023 and plans to launch Nuceiva® in select European countries later this year.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, announced participation in the Virtual 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, from 4:20 PM to 4:50 PM ET. The event will showcase Evolus' focus on delivering breakthrough products, including its FDA-approved neurotoxin, Jeuveau®. Interested parties can access an audio webcast on the investor relations section of Evolus’ website, with a replay available for 90 days.
Evolus, Inc. (NASDAQ: EOLS) reported preliminary unaudited net revenues of approximately